Modulation of the myeloid compartment of the immune system by angiogenic- and kinase inhibitor-targeted anti-cancer therapies

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Targeted therapies were rationally designed to inhibit molecular pathways in tumor cells critically involved in growth and survival; however, many drugs used in targeted therapies may affect the immune system. In addition, selected conventional chemotherapeutic agents have also been reported to be endowed with direct or indirect effects on immunity, for instance via immunogenic death of tumors. Thus, cancer therapies may have off-target effects, some of which are directed to the immune system. Here, we will review some of these effects in specific therapeutic approaches. We will examine the modulation of the immune contexture in human sarcoma and melanoma induced by anti-angiogenic therapies and by BRAF inhibitors, respectively. We will then discuss how the anti-tumor agent trabectedin is selectively cytotoxic to cells of the monocytic-macrophage lineage and how these immune-related effects can be part of the response to treatment.

Original languageEnglish
Pages (from-to)83-89
Number of pages7
JournalCancer Immunology, Immunotherapy
Volume64
Issue number1
DOIs
Publication statusPublished - Jan 1 2015

Fingerprint

Angiogenesis Inhibitors
Immune System
Phosphotransferases
trabectedin
Neoplasms
Therapeutics
Sarcoma
Immunity
Melanoma
Macrophages
Survival
Growth
Pharmaceutical Preparations

Keywords

  • Anti-angiogenic therapies
  • BRAF inhibitors
  • Immune responses
  • NIBIT 2013
  • Targeted therapies
  • Tumor-associated myeloid cells

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Immunology
  • Immunology and Allergy
  • Medicine(all)

Cite this

@article{e977f43b8cdf43058b00d2848e22adf0,
title = "Modulation of the myeloid compartment of the immune system by angiogenic- and kinase inhibitor-targeted anti-cancer therapies",
abstract = "Targeted therapies were rationally designed to inhibit molecular pathways in tumor cells critically involved in growth and survival; however, many drugs used in targeted therapies may affect the immune system. In addition, selected conventional chemotherapeutic agents have also been reported to be endowed with direct or indirect effects on immunity, for instance via immunogenic death of tumors. Thus, cancer therapies may have off-target effects, some of which are directed to the immune system. Here, we will review some of these effects in specific therapeutic approaches. We will examine the modulation of the immune contexture in human sarcoma and melanoma induced by anti-angiogenic therapies and by BRAF inhibitors, respectively. We will then discuss how the anti-tumor agent trabectedin is selectively cytotoxic to cells of the monocytic-macrophage lineage and how these immune-related effects can be part of the response to treatment.",
keywords = "Anti-angiogenic therapies, BRAF inhibitors, Immune responses, NIBIT 2013, Targeted therapies, Tumor-associated myeloid cells",
author = "Chiara Castelli and Licia Rivoltini and Monica Rodolfo and Marcella Tazzari and Cristina Belgiovine and Paola Allavena",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/s00262-014-1576-1",
language = "English",
volume = "64",
pages = "83--89",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "1",

}

TY - JOUR

T1 - Modulation of the myeloid compartment of the immune system by angiogenic- and kinase inhibitor-targeted anti-cancer therapies

AU - Castelli, Chiara

AU - Rivoltini, Licia

AU - Rodolfo, Monica

AU - Tazzari, Marcella

AU - Belgiovine, Cristina

AU - Allavena, Paola

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Targeted therapies were rationally designed to inhibit molecular pathways in tumor cells critically involved in growth and survival; however, many drugs used in targeted therapies may affect the immune system. In addition, selected conventional chemotherapeutic agents have also been reported to be endowed with direct or indirect effects on immunity, for instance via immunogenic death of tumors. Thus, cancer therapies may have off-target effects, some of which are directed to the immune system. Here, we will review some of these effects in specific therapeutic approaches. We will examine the modulation of the immune contexture in human sarcoma and melanoma induced by anti-angiogenic therapies and by BRAF inhibitors, respectively. We will then discuss how the anti-tumor agent trabectedin is selectively cytotoxic to cells of the monocytic-macrophage lineage and how these immune-related effects can be part of the response to treatment.

AB - Targeted therapies were rationally designed to inhibit molecular pathways in tumor cells critically involved in growth and survival; however, many drugs used in targeted therapies may affect the immune system. In addition, selected conventional chemotherapeutic agents have also been reported to be endowed with direct or indirect effects on immunity, for instance via immunogenic death of tumors. Thus, cancer therapies may have off-target effects, some of which are directed to the immune system. Here, we will review some of these effects in specific therapeutic approaches. We will examine the modulation of the immune contexture in human sarcoma and melanoma induced by anti-angiogenic therapies and by BRAF inhibitors, respectively. We will then discuss how the anti-tumor agent trabectedin is selectively cytotoxic to cells of the monocytic-macrophage lineage and how these immune-related effects can be part of the response to treatment.

KW - Anti-angiogenic therapies

KW - BRAF inhibitors

KW - Immune responses

KW - NIBIT 2013

KW - Targeted therapies

KW - Tumor-associated myeloid cells

UR - http://www.scopus.com/inward/record.url?scp=84925024926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925024926&partnerID=8YFLogxK

U2 - 10.1007/s00262-014-1576-1

DO - 10.1007/s00262-014-1576-1

M3 - Article

C2 - 24993564

AN - SCOPUS:84925024926

VL - 64

SP - 83

EP - 89

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 1

ER -